@article{ecf03a63eb624a98aa81b194fe8da8ce,
title = "Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin",
keywords = "HSCT, acute lymphoblastic leukaemia, inotuzumab ozogamicin, relapsed, treatment cycles",
author = "Cassaday, {Ryan D.} and Marks, {David I.} and DeAngelo, {Daniel J.} and Jabbour, {Elias J.} and Advani, {Anjali S.} and Susan O'Brien and Tao Wang and Alexander Neuhof and Erik Vandendries and Kantarjian, {Hagop M.} and Wendy Stock and Matthias Stelljes",
note = "Funding Information: This study was sponsored by Pfizer. Medical writing support was provided by Shuang Li, PhD, of Engage Scientific Solutions, and was funded by Pfizer. ",
year = "2020",
month = nov,
day = "1",
doi = "10.1111/bjh.17029",
language = "English (US)",
volume = "191",
pages = "e77--e81",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",
}